 The Data Safety Monitoring Board DSMB for A5202 met in January 2008 to review the study. After reviewing the study information, the DSMB noted that certain study regimens were significantly less effective than others. Specifically, ABC3TC-containing regimens were not as effective in controlling the virus as TDFFTC-containing regimens for participants entering the study with high viral loads. The DSMB also commented that participants assigned to ABC3TC had a shorter time until they experienced side effects than participants assigned to TDFFTC. The DSMB had no safety concerns for the other drug comparisons. 